Monday, July 25, 2016

Merck (MRK) Stock Down, Ebola Vaccine Under 'Accelerated' FDA Review

… to $58.19 this morning despite the company’s announcement that its experimental Ebola vaccine V920 has received accelerated review status in the … Full Article http://j.gs/5sTq

Click here to read full article
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)